ONO Pharmaceutical Co., Ltd.

ONO Pharmaceutical

In September 2018, we entered into a collaboration with ONO Pharmaceutical to develop and commercialize two off-the-shelf CAR-T cell product candidates. The collaboration brings together ONO’s global leadership and proven track record in oncology and our expertise with induced pluripotent stem cells (iPSC) and CAR-T cell therapies. Under the collaboration, using our proprietary iPSC platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality. Fate retains global responsibility for one of the candidates, with ONO having an option to assume responsibilities in Asia. For the second candidate, ONO has an option to assume global responsibility, with Fate retaining the right to co-develop and co-commercialize in the United States and Europe.